Persistence of nasopharyngeal pneumococcal vaccine serotypes and increase of nonvaccine serotypes among vaccinated infants and their mothers 5 years after introduction of pneumococcal conjugate vaccine 13 in the Gambia

Clinical Infectious Diseases

Volumn 68, Issue 9, 2019, Pages 1512-1521

  Usuf, Effua ^a   Bottomley, Christian ^a   Bojang, Ebrima ^a   Cox, Isatou ^a   Bojang, Abdoulie ^a   Gladstone, Rebecca ^b   Kampmann, Beate ^a   Hill, Philip C ^c   Roca, Anna ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Herd effect; Nontypeable; Pneumococcal carriage; Serotypes

Indexed keywords

ANTIBIOTIC AGENT; PNEUMOCOCCUS VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATION; CROSS-SECTIONAL STUDY; EDUCATIONAL STATUS; FEMALE; GAMBIA; GENOMICS; HEALTH SURVEY; HUMAN; INFANT; MALE; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; THROAT CULTURE; VACCINATION; WHOLE GENOME SEQUENCING; CLASSIFICATION; GENETICS; HERD IMMUNITY; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; MOTHER; NASOPHARYNX; PROCEDURES; STREPTOCOCCUS PNEUMONIA;

ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNITY, HERD; INFANT; MALE; MOTHERS; NASOPHARYNX; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; SEROGROUP; STREPTOCOCCUS PNEUMONIAE; VACCINATION; WHOLE GENOME SEQUENCING;

EID: 85065979138     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciy726     Document Type: Article

References (47)

1. Wahl B, O’Brien KL, Greenbaum A, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health 2018; 6:e744–57.
2. Esposito S, Tansey S, Thompson A, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol 2010; 17:1017–26.
3. WHO Publication. Pneumococcal vaccines WHO position paper—2012— recommendations. Vaccine 2012; 30:4717–8.
4. Gavi. Supply and procurement roadmap: pneumococcal vaccine. 2017. Available at: https://www.gavi.org/library/gavi-documents/supply-procurement/pneumococcal-vaccine-roadmap-public-summary/. Accessed 21 May 2018.
5. Davis SM, Deloria-Knoll M, Kassa HT, O’Brien KL. Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects. Vaccine 2013; 32:133–45.
6. van Hoek AJ, Sheppard CL, Andrews NJ, et al. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England. Vaccine 2014; 32:4349–55.
7. Sigurdsson S, Erlendsdóttir H, Quirk SJ, et al. Pneumococcal vaccination: direct and herd effect on carriage of vaccine types and antibiotic resistance in Icelandic children. Vaccine 2017; 35:5242–8.
8. Hammitt LL, Bruden DL, Butler JC, et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis 2006; 193:1487–94.
9. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011; 11:760–8.
10. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011; 378:1962–73.
11. Feikin DR, Kagucia EW, Loo JD, et al; Serotype Replacement Study Group. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med 2013; 10:e1001517.
12. Whitney CG, Farley MM, Hadler J, et al; Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348:1737–46.
13. Gladstone RA, Jefferies JM, Tocheva AS, et al. Five winters of pneumococcal serotype replacement in UK carriage following PCV introduction. Vaccine 2015; 33:2015–21.
14. Croucher NJ, Kagedan L, Thompson CM, et al. Selective and genetic constraints on pneumococcal serotype switching. PLoS Genet 2015; 11:e1005095.
15. Mackenzie GA, Hill PC, Jeffries DJ, et al. Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study. Lancet Infect Dis 2016; 16:703–11.
16. Roca A, Bojang A, Bottomley C, et al; Pneumo13 Study Group. Effect on nasopharyngeal pneumococcal carriage of replacing PCV7 with PCV13 in the Expanded Programme of Immunization in The Gambia. Vaccine 2015; 33:7144–51.
17. World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2018 global summary: WHO UNICEF estimates time series for Gambia. Geneva, Switzerland: World Health Organization. Available at: http://apps.who.int/immunization_monitoring/globalsummary/estimates?c=GMB. Accessed 15 July 2018.
18. O’Brien KL, Nohynek H; World Health Organization Pneumococcal Vaccine Trials Carriage Working Group. Report from a WHO Working Group: standard method for detecting upper respiratory carriage of Streptococcus pneumoniae. Pediatr Infect Dis J 2003; 22:e1–11.
19. Satzke C, Turner P, Virolainen-Julkunen A, et al; WHO Pneumococcal Carriage Working Group. Standard method for detecting upper respiratory carriage of Streptococcus pneumoniae: updated recommendations from the World Health Organization Pneumococcal Carriage Working Group. Vaccine 2013; 32:165–79.
20. Porter BD, Ortika BD, Satzke C. Capsular serotyping of Streptococcus pneumoniae by latex agglutination. J Vis Exp 2014 :51747.
21. Page AJ, Taylor B, Delaney AJ, et al. SNP-sites: rapid efficient extraction of SNPs from multi-FASTA alignments. Microb Genom 2016; 2:e000056.
22. Stamatakis A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. Bioinformatics 2014; 30:1312–3.
23. Epping L, van Tonder A, Gladstone R, et al. SeroBA: rapid high-throughput serotyping of Streptococcus pneumoniae from whole genome sequence data. Microb Genom. 2018; 4. doi:10.1099/mgen.0.000186
24. Seemann T. Prokka: rapid prokaryotic genome annotation. Bioinformatics 2014; 30:2068–9.
25. Bentley SD, Aanensen DM, Mavroidi A, et al. Genetic analysis of the capsular biosynthetic locus from all 90 pneumococcal serotypes. PLoS Genet 2006; 2:e31.
26. Carver TJ, Rutherford KM, Berriman M, Rajandream MA, Barrell BG, Parkhill J. ACT: the Artemis comparison tool. Bioinformatics 2005; 21:3422–3.
27. Usuf E, Bojang A, Camara B, et al. Maternal pneumococcal nasopharyngeal carriage and risk factors for neonatal carriage after the introduction of pneumococcal conjugate vaccines in The Gambia. Clin Microbiol Infect 2018; 24:389–95.
28. Navne JE, Koch A, Slotved HC, et al. Effect of the 13-valent pneumococcal conjugate vaccine on nasopharyngeal carriage by respiratory pathogens among Greenlandic children. Int J Circumpolar Health 2017; 76:1309504.
29. Wouters I, Van Heirstraeten L, Desmet S, et al; NPcarriage Study Group. Nasopharyngeal S. pneumoniae carriage and density in Belgian infants after 9 years of pneumococcal conjugate vaccine programme. Vaccine 2018; 36:15–22.
30. Collins DA, Hoskins A, Snelling T, et al. Predictors of pneumococcal carriage and the effect of the 13-valent pneumococcal conjugate vaccination in the Western Australian aboriginal population. Pneumonia (Nathan) 2017; 9:14.
31. Bottomley C, Roca A, Hill PC, Greenwood B, Isham V. A mathematical model of serotype replacement in pneumococcal carriage following vaccination. J R Soc Interface 2013; 10:20130786.
32. Horacio AN, Silva-Costa C, Lopes JP, Ramirez M, Melo-Cristino J; Portuguese Group for the Study of Streptococcal I. Serotype 3 remains the leading cause of invasive pneumococcal disease in adults in Portugal (2012–2014) despite continued reductions in other 13-valent conjugate vaccine serotypes. Front Microbiol 2016; 7:1616.
33. Roca A, Dione MM, Bojang A, et al. Nasopharyngeal carriage of pneumococci four years after community-wide vaccination with PCV-7 in The Gambia: long-term evaluation of a cluster randomized trial. PLoS One 2013; 8:e72198.
34. Loo JD, Conklin L, Fleming-Dutra KE, et al. Systematic review of the indirect effect of pneumococcal conjugate vaccine dosing schedules on pneumococcal disease and colonization. Pediatr Infect Dis J 2014; 33(suppl 2):S161–71.
35. Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study. Lancet Infect Dis 2018; 18:441–51.
36. Roca A, Hill PC, Townend J, et al. Effects of community-wide vaccination with PCV-7 on pneumococcal nasopharyngeal carriage in the Gambia: a cluster-randomized trial. PLoS Med 2011; 8:e1001107.
37. Waight PA, Andrews NJ, Ladhani NJ, Sheppard CL, Slack MP, Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis 2015; 15:629.
38. Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015; 15:301–9.
39. Zuccotti G, Mameli C, Daprai L, et al; PneuMi Study Group (PMSG). Serotype distribution and antimicrobial susceptibilities of nasopharyngeal isolates of Streptococcus pneumoniae from healthy children in the 13-valent pneumococcal conjugate vaccine era. Vaccine 2014; 32:527–34.
40. Steens A, Caugant DA, Aaberge IS, Vestrheim DF. Decreased carriage and genetic shifts in the Streptococcus pneumoniae population after changing the seven-valent to the thirteen-valent pneumococcal vaccine in Norway. Pediatr Infect Dis J 2015; 34:875–83.
41. Bojang A, Jafali J, Egere UE, et al. Seasonality of pneumococcal nasopharyngeal carriage in rural Gambia determined within the context of a cluster randomized pneumococcal vaccine trial. PLoS One 2015; 10:e0129649.
42. Chen HH, Hsu MH, Wu TL, et al. Non-typeable Streptococcus pneumoniae infection in a medical center in Taiwan after wide use of pneumococcal conjugate vaccine. J Microbiol Immunol Infect 2018; doi:10.1016/j.jmii.2018.04.001. [Epub ahead of print].
43. Keller LE, Robinson DA, McDaniel LS. Nonencapsulated Streptococcus pneumoniae: emergence and Pathogenesis. MBio 2016; 7:e01792.
44. Park IH, Geno KA, Sherwood LK, Nahm MH, Beall B. Population-based analysis of invasive nontypeable pneumococci reveals that most have defective capsule synthesis genes. PLoS One 2014; 9:e97825.
45. Mohale T, Wolter N, Allam M, et al. Genomic analysis of nontypeable pneumococci causing invasive pneumococcal disease in South Africa, 2003–2013. BMC Genom 2016; 17:470.
46. Whitney CG. Examining duration of protection: should a booster dose be part of all infant pneumococcal conjugate vaccine programs? Clin Infect Dis 2018; 67:375–7.
47. Hill PC, Cheung YB, Akisanya A, et al. Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian infants: a longitudinal study. Clin Infect Dis 2008; 46:807–14.